The Immunobiological Technology Institute

The Immunobiological Technology Institute (ITI) is a Japanese biotechnology company specializing in the research and development of high-specificity antibodies and diagnostic reagents, primarily for neurodegenerative diseases. The institute is recognized for its expertise in targeting amyloid beta oligomers and prion proteins, providing critical tools for both basic research and the development of therapeutic candidates. ITI operates a research-driven business model that includes the production of specialized monoclonal antibodies, diagnostic kit development, and collaborative drug discovery projects. By focusing on the molecular mechanisms of protein misfolding, the company aims to advance early diagnosis and treatment options for Alzheimer's disease and related conditions.